Objective
To systematically evaluate the association between Caveolin-1 and gastric cancer, as well as its clinical pathologic features.
Methods
Databases including Wanfang, VIP, CNKI and PubMed were searched to identify case-control studies involving the association between Caveolin-1 and gastric cancer as well as its clinical pathologic features from January 2000 to May 2017. The literatures were screened and the methodological quality was assessed, then RevMan 5.3 software was used to conduct Meta-analysis.
Results
A total of 12 case-control studies were collected after screening, including 1 380 cases of gastric cancer, with Caveolin-1 expressed positive in 286 cases; 295 cases of non-carcinoma control, with Caveolin-1 expressed positive in 264 cases; 238 cases of precancerous lesions of gastric cancer, with Caveolin-1 expressed positive in 180 cases. Results of Meta-analysis indicated that: as for Caveolin-1 expression, significant differences were found in non-carcinoma vs. gastric cancer [odds ratio (OR)=23.74, 95% confidence interval (CI) (15.19, 37.11), P<0.000 01], precancerous lesions of gastric cancer vs. gastric cancer [OR=6.58, 95%CI (4.52, 9.58), P<0.000 01], and non-carcinoma control vs. precancerous lesions of gastric cancer [OR=2.88, 95%CI (1.58, 5.25), P=0.000 6]. Significant differences were also found between Caveolin-1 expression and gastric cancer clinical pathologic features in undifferentiated vs. differentiated tissue [OR=0.48, 95%CI (0.33, 0.70), P=0.000 1], and without vs. with lymph node metastasis [OR=3.19, 95%CI (1.77, 5.74), P=0.000 1].
Conclusions
Caveolin-1 expression is lesser in most gastric cancer patients than in the controls, and is closely associated with its clinical pathologic features. Due to limited quantity and quality of included studies, more high quality studies are needed to verify the conclusion of Caveolin-1 as a tumor marker in gastric cancer.
ObjectiveTo investigate the anticoagulant drug treatment decision for patients with renal contusion and acute pulmonary embolism, and to enhance the level of treatment for this disease. MethodsA retrospective analysis of the clinical data of a patient with renal contusion and acute pulmonary embolism treated at the West China Hospital of Sichuan University, along with a relevant literature review. Databases including PubMed, Ovid Medline, Embase, VIP, Wanfang and Chinese National Knowledge infrastructure were searched using the keywords as “Pulmonary embolism” AND “Hemorrhage”from January 1983 to December 2023. ResultThe patient was a 21-year-old male who presented with right kidney contusion for 5 days and dyspnea for 1 day. The abdominal CT scan revealed a ruptured right kidney accompanied by hemorrhage and hematoma in the surrounding tissue. Abdomen ultrasound: a low echogenic area measuring approximately 10.6 cm×2.8 cm is noted around the right kidney. The CT pulmonary angiography (CTPA) demonstrated filling defects at the bifurcation of the pulmonary trunk, as well as within the upper and lower lobes of both lungs and their respective branches. The blood gas analysis of patient indicated (face mask oxygen therapy at 10 L/min, oxygenation index of 120): pH 7.456, PCO2 24.9 mm Hg, PO2 73.2 mm Hg. His myocardial markers were Myoglobin: 79.21 ng/ml, Troponin T: 58.7 ng/L, BNP: 2062 ng/L. The patient was diagnosed with renal contusion and pulmonary embolism, and was treated with subcutaneous heparin（initial dose is given as an 80 IU/kg intravenous bolus, followed by a continuous infusion of 12-18 IU/kg/h） and low-molecular-weight heparin at a dose of 0.8 ml every 12 hours one after another for anticoagulation, along with symptomatic treatment. Following the intervention, the patient's respiratory distress showed significant improvement, and subsequent arterial blood gas analysis indicated enhanced oxygenation. Then, the anticoagulant medication was adjusted to oral rivaroxaban anticoagulation for 6 months, follow-up CTPA scan revealed complete resolution of the pulmonary embolism and the abdominal CT scan indicated a reduction in the extent of patchy low-density shadows surrounding the right kidney, leading to the discontinuation of anticoagulation therapy. After searching the above-mentioned databases, total of 26 articles were identified that reported on 30 patients diagnosed with high-risk bleeding and acute pulmonary embolism; among these, 3 patients succumbed while 27 exhibited clinical improvement. ConclusionsPatients with renal contusion and acute pulmonary embolism can be safely and effectively treated with low-dose heparin anticoagulation under close monitoring. High-risk bleeding patients with acute pulmonary embolism present a significant challenge in clinical practice. After weighing the risks of bleeding disorders and the adverse outcomes of pulmonary embolism, it is necessary to find the optimal balance between anticoagulation and bleeding. Consequently, the formulation of personalized treatment strategies in accordance with established guidelines can enhance patient outcomes.
ObjectiveTo investigate the safety and efficacy of bronchial thermoplasty and omalizumab after bronchial thermoplasty in severe asthma.Methods Collect patients with severe asthma who underwent BT in our hospital from January 2015 to January 2025. Assess the efficacy, asthma control, and pulmonary function 1 year after surgery,divide into uncontrolled, partially controlled, and completely controlled groups based on efficacy. Allergen and total serum IgE were conducted in partially controlled and uncontrolled patients, and those suitable for treatment with omalizumab underwent a 1-year treatment.The efficacy, asthma control, quality of life, lung function, and adverse reactions of patients in the bronchial thermoplasty group (BT group) and the omalizumab after bronchial thermoplasty group(BT-omalizumab group)were evaluated. Resultsshow that after one year of BT treatment, the ACT assessment of patients is better than before treatment (P<0.05), but more than half of patients still have poor control; The level of type 2 inflammation in the partially controlled and uncontrolled groups was higher than that in the completely controlled group (P<0.05), while there was no significant difference between the partially controlled and uncontrolled groups (P>0.05). After 1 year of BT treatment, the number of acute attacks in patients decreased, and the proportion of patients using OCS decreased, the hospitalization days shortened, and the quality of life (MiniAQLQ score) improved (all P<0.05). Compared with before BT, the FEV1, FEV1%, FEV1/FVC, and PEF of patients improved after 1 year of treatment (all P<0.05), while FVC, FVC%, and MMEF% showed no significant changes (all P>0.05). Compared with BT group, BT-omalizumab group can further improve FEV1, FEV1%, FEV1/FVC, and PEF (all P<0.05), while there was no significant difference in FVC, FVC%, and MMEF% between the two treatment groups (all P>0.05 ). The BT-omalizumab group can significantly shorten hospitalization days, improve asthma control and quality of life (all P<0.05); The combination group can further reduce the number of acute attacks compared to the BT group, but there is no statistical difference (P>0.05). There was no statistically significant difference in the occurrence of adverse reactions between the two groups (all P>0.05).Conclusions BT can reduce acute asthma attacks and OCS use, shorten hospitalization time, improve asthma control, quality of life and lung function. However, the effect is not ideal in patients with type 2 inflammatory phenotype. Treatment with omalizumab can more effectively control asthma, shorten hospitalization time, improve lung function, enhance quality of life, and is safer for these patients.
